GLP-1 Receptor Agonists Aid Weight Loss Without Worsening IBD, suggests study
A meta-analysis of 10,362 patients with inflammatory bowel disease has found that GLP-1 receptor agonists are safe and effective for weight loss, producing a 6.67% reduction in total body weight and a 2.48 kg/m² drop in BMI, without increasing inflammatory bowel disease activity.
Obesity is increasingly recognized as a common comorbidity in patients with inflammatory bowel disease (IBD). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for weight reduction and cardiometabolic risk management. However, their safety and effectiveness in individuals with inflammatory bowel disease remain uncertain. They conducted a systematic review through June 2025 to identify studies involving adult patients with inflammatory bowel disease treated with GLP-1RAs. Primary outcomes included hospitalization, corticosteroid use, treatment escalation, risk of flare, and inflammatory bowel disease-related surgery. Secondary outcomes were changes in weight and body mass index (BMI).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.